---
document_datetime: 2024-11-11 13:31:38
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/alprolix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: alprolix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 6.652617
conversion_datetime: 2025-12-28 19:03:40.168083
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Alprolix

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0047            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 06/11/2024                          |                                             | Annex II and PL                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0046/G           | This was an application for a group of variations. B.II.d.2.e - Change in test procedure for the finished product - Update of the test procedure to comply with the updated general monograph in the Ph. Eur. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)   | 05/11/2024   | n/a        |             |                                                                                                                                            |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| N/0043              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                       | 11/10/2024   | n/a        |             |                                                                                                                                            |
| IB/0045             | B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation                                                                                                                                                                                                                                    | 01/10/2024   | n/a        |             |                                                                                                                                            |
| IB/0044/G           | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.a.z - Change in manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                 | 26/09/2024   | n/a        |             |                                                                                                                                            |
| PSUSA/10499 /202303 | Periodic Safety Update EU Single assessment - eftrenonacog alfa                                                                                                                                                                                                                                                                                        | 09/11/2023   | 05/01/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10499/202303. |
| IB/0042/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                     | 24/10/2023   | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | B.II.d.2.z - Change in test procedure for the finished product - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                              |            |            |          |                     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|---------------------|
| IA/0040/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of | 18/11/2022 | n/a        |          | manufacturing sites |
| IB/0039   | B.I.c.1.z - Change in immediate packaging of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                 | 31/01/2022 | n/a        |          |                     |
| IB/0038   | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                          | 03/12/2021 | n/a        |          |                     |
| II/0036/G | This was an application for a group of variations. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test                                                                                                                                                                                                                 | 09/09/2021 | 14/10/2022 | Annex II |                     |

<div style=\"page-break-after: always\"></div>

|         | method at the site is a biol/immunol method B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method   |            |            |                                  |                                                                                                                                                                                                                                                                        |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0037 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 17/05/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                        |
| R/0032  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 10/12/2020 | 11/02/2021 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Alprolix in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0035 | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 18/12/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                     | material/intermediate                                                                                                                                                                                        |            |            |             |                                                                                                                                                                                                    |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0034             | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                 | 28/10/2020 | n/a        |             |                                                                                                                                                                                                    |
| IB/0033             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                       | 28/10/2020 | n/a        |             |                                                                                                                                                                                                    |
| II/0029             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                            | 03/09/2020 | 19/10/2020 | SmPC and PL | Update of sections 4.2, 4.8 and 5.1 of the SmPC as well as PL section 4 to include paediatric data on Previously Untreated Patients (PUPs) following the completion of a phase III study 998HB303. |
| PSUSA/10499 /202003 | Periodic Safety Update EU Single assessment - eftrenonacog alfa                                                                                                                                              | 01/10/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                  |
| IB/0031             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 13/07/2020 | n/a        |             |                                                                                                                                                                                                    |
| II/0028             | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                          | 12/03/2020 | n/a        |             |                                                                                                                                                                                                    |
| II/0026             | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for                   | 12/12/2019 | n/a        |             |                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10499 /201903 | Periodic Safety Update EU Single assessment - eftrenonacog alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 03/10/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0027           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 26/08/2019 | n/a        |                        |                                   |
| IB/0024             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                 | 08/05/2019 | n/a        |                        |                                   |
| PSUSA/10499 /201809 | Periodic Safety Update EU Single assessment - eftrenonacog alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11/04/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| II/0021             | Update of sections 4.8 and 5.1 of the SmPC to include new clinical efficacy and safety data on long- term treatment with Alprolix. The submission includes integrated evaluation of data from the extension study 9HB01EXT (BYOND) which was submitted in a previous P46 procedure and the pivotal parent studies. The PL is updated accordingly. In addition, the MAH took the opportunity to update the product information to comply with the latest version of the 'Excipients in the labelling and package leaflet of medicinal products for human use\"guideline. The list of local representatives has | 21/02/2019 | 11/02/2020 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | been updated and other minor editorial changes have been included in the PL. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                         |            |            |      |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0023             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                       | 17/01/2019 | n/a        |      |                                                                                                                                            |
| II/0020             | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method | 22/11/2018 | n/a        |      |                                                                                                                                            |
| PSUSA/10499 /201803 | Periodic Safety Update EU Single assessment - eftrenonacog alfa                                                                                                                                                                                                        | 04/10/2018 | n/a        |      | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10499 /201709 | Periodic Safety Update EU Single assessment - eftrenonacog alfa                                                                                                                                                                                                        | 26/04/2018 | 06/07/2018 | SmPC | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10499/201709. |
| IA/0018             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                          | 18/04/2018 | n/a        |      |                                                                                                                                            |
| IB/0017             | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                            | 21/03/2018 | n/a        |      |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IB/0016             | B.I.b.1.i - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Where there is no monograph in the European/National Ph. for the AS, a change in specification from in-house to a non- official/third country Ph.      | 15/03/2018   | n/a   |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IB/0015             | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                 | 05/03/2018   | n/a   |                                   |
| IB/0014             | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                               | 23/01/2018   | n/a   |                                   |
| IB/0012             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                  | 15/12/2017   | n/a   |                                   |
| PSUSA/10499 /201703 | Periodic Safety Update EU Single assessment - eftrenonacog alfa                                                                                                                                                                                                            | 28/09/2017   | n/a   | PRAC Recommendation - maintenance |
| IA/0010             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                              | 20/07/2017   | n/a   |                                   |
| II/0006/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process | 20/07/2017   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|         | of the AS B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.c.1.c - Change in immediate packaging of the AS - Liquid ASs (non sterile) B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the   |            |            |                     |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|
| IB/0009 | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 20/06/2017 | n/a        |                     |
| IB/0007 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 13/06/2017 | 07/06/2018 | SmPC, Labelling and |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                       |            |            | PL                     |                                                                                                                                            |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10499 /201609 | Periodic Safety Update EU Single assessment - eftrenonacog alfa                                                                                                                                                       | 20/04/2017 | 23/06/2017 |                        | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10499/201609. |
| IB/0002             | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method | 14/12/2016 | n/a        |                        |                                                                                                                                            |
| N/0004              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                      | 26/10/2016 | 23/06/2017 | Labelling              |                                                                                                                                            |
| IAIN/0003           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                    | 17/10/2016 | n/a        |                        |                                                                                                                                            |
| T/0001              | Transfer of marketing authorisation from Biogen Idec Ltd to Swedish Orphan Biovitrum AB (publ). Transfer of Marketing Authorisation                                                                                   | 25/08/2016 | 30/09/2016 | SmPC, Labelling and PL |                                                                                                                                            |